Dr. Adusumilli studies nasopharyngeal carcinoma, a form of head and neck cancer most common in Southeast Asia and North Africa. His research involves analyzing cancerous and healthy tissue samples to identify differences in proteins, which could lead to better diagnostic techniques for patients. He also explores prostate cancer, looking for specific markers that differentiate it from benign conditions like benign prostatic hyperplasia. By understanding how these proteins behave in different conditions, Dr. Adusumilli aims to enhance early detection and personalize treatment options for cancer patients.
Key findings
In his 2024 study, 3,341 proteins were identified in nasopharyngeal carcinoma samples, with 1,507 found to be significantly different from healthy tissues.
His 2025 research identified 291 proteins in nasopharyngeal carcinoma patients, revealing three that might predict disease progression.
In a study of breast cancer, 32 proteins showed different levels between diagnosed women and their healthy sisters, highlighting challenges in early detection.
In his 2018 study, certain proteins were higher in blood samples from prostate cancer patients, helping to distinguish them from those with benign prostatic hyperplasia.
From analyzing 5,000 cancer patients, 26% were found to have genetic mutations that could be targeted for specific treatment options.
Frequently asked questions
Does Dr. Adusumilli study nasopharyngeal carcinoma?
Yes, Dr. Adusumilli conducts extensive research on nasopharyngeal carcinoma, focusing on identifying proteins that can help in diagnosis and tracking the disease.
What treatments has Dr. Adusumilli researched?
His research aims to identify biomarkers and genetic information that can lead to personalized treatment options for cancer patients.
Is Dr. Adusumilli's work relevant to patients with prostate cancer?
Yes, his studies on prostate cancer focus on discovering blood protein markers that can help differentiate between prostate cancer and benign conditions.
How does Dr. Adusumilli's research help in cancer detection?
By identifying specific proteins that are present in cancerous tissues, his research contributes to the development of more reliable diagnostic tests for early detection of various cancers.
What is the impact of Dr. Adusumilli's work on breast cancer research?
His research evaluates protein levels in pre-diagnostic samples, aiming to improve methods for discovering early indicators of breast cancer.
Publications in plain English
Integrated Plasma and Tumor Proteomics of Nasopharyngeal Carcinoma in a Moroccan Cohort.
2025
International journal of molecular sciences
Reffai A, Hori M, Adusumilli R, Bermudez A, Haddad H +4 more
Plain English This study looked at nasopharyngeal carcinoma (NPC), a type of cancer that mainly affects people in Southeast Asia and North Africa, focusing on samples from Morocco. Researchers analyzed blood and tumor samples from 25 individuals, identifying 291 proteins and 16 that were present in different amounts between cancer patients and healthy people. They found three proteins that may help predict how the disease progresses and four that could aid in diagnosis, which is important because there aren’t many biomarkers for this type of cancer.
Who this helps: This helps patients with nasopharyngeal carcinoma and their doctors by providing potential new tools for diagnosis and tracking the disease.
A Proteomic Analysis of Nasopharyngeal Carcinoma in a Moroccan Subpopulation.
2024
Cancers
Reffai A, Hori M, Adusumilli R, Bermudez A, Bouzoubaa A +3 more
Plain English This study examined nasopharyngeal carcinoma (NPC), a type of head and neck cancer, specifically in patients from Morocco and North Africa. Researchers analyzed tissue samples from 41 NPC patients, finding 3,341 proteins and identifying 1,507 of them as significantly different from healthy tissues. Certain proteins, related to immune response and cell survival, were more active in cancerous tissues, which may help in discovering biomarkers for early diagnosis and treatment.
Who this helps: This benefits patients with nasopharyngeal carcinoma and healthcare providers in North Africa.
Semantic workflows for benchmark challenges: Enhancing comparability, reusability and reproducibility.
2019
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
Srivastava A, Adusumilli R, Boyce H, Garijo D, Ratnakar V +5 more
Plain English This study focused on improving how bioinformatics challenges evaluate competing methods by using a new system called WINGS that allows researchers to submit detailed workflows. The researchers found that by providing a clear, structured methodology for submissions, it becomes easier to compare how different approaches affect results, which is important because even small changes in parameters can lead to large differences in outcomes. This matters because it enhances the ability to reproduce, reuse, and understand bioinformatics results, making the whole process more efficient and reliable.
Who this helps: This helps researchers and scientists in bioinformatics by providing clearer comparisons of methodologies and results.
Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
2018
Scientific reports
Totten SM, Adusumilli R, Kullolli M, Tanimoto C, Brooks JD +2 more
Plain English This study examined the differences in blood proteins between prostate cancer and a non-cancerous condition called benign prostatic hyperplasia (BPH). Researchers found that certain proteins, such as CD5L and CFP, were higher in prostate cancer samples, while specific changes in protein structures (glycoforms) also distinguished the two conditions. Understanding these differences is important because it could lead to better tests for accurately diagnosing prostate cancer and distinguishing it from benign prostate issues.
Who this helps: Patients with prostate issues, including those at risk for prostate cancer.
Plain English This study looked at a tool called ProteoWizard's msConvert, which helps researchers convert data from different mass spectrometry machines into a common format that can be analyzed more easily. The findings explain how to use this software effectively, highlighting the different options available for conversion and what those options mean for the analysis process. This is important because using a standard data format allows scientists to collaborate better and improve their research outcomes.
Who this helps: This helps researchers working with mass spectrometry data.
Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.
2017
Biomarker research
Yeh CY, Adusumilli R, Kullolli M, Mallick P, John EM +1 more
Plain English This research examined the levels of proteins in blood samples from women diagnosed with breast cancer, comparing them to samples from their healthy sisters. While the study found that 32 proteins had different levels between the two groups, none of these differences were strong enough to be reliably identified after accounting for potential errors. The findings highlight the challenges in measuring proteins accurately and the need to improve methods for discovering early cancer indicators in blood tests.
Who this helps: This helps researchers and clinicians working on early cancer detection and biomarker development.
Protein biomarkers on tissue as imaged via MALDI mass spectrometry: A systematic approach to study the limits of detection.
2016
Proteomics
van de Ven SM, Bemis KD, Lau K, Adusumilli R, Kota U +4 more
Plain English This study looked at how well a technique called MALDI mass spectrometry imaging can detect proteins in tissue samples. Researchers found that they could reliably identify proteins when they were present in high amounts, with good precision and a spatial resolution of 200 micrometers. They also determined that this method can detect proteins at concentrations ranging from micromolar to millimolar levels, providing a foundation for discovering new protein biomarkers for diseases.
Who this helps: This research benefits scientists and researchers working on developing new diagnostic tools for patients.
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
2014
The Journal of molecular diagnostics : JMD
MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R +25 more
Plain English This study examined the genetic make-up of cancer patients to better understand the mutations that can affect their treatment. Out of 5,000 patients tested, 26% had mutations that could lead to specific treatment options. This research is important because it shows how knowing a patient's genetic information can help personalize their cancer care, potentially leading to better outcomes.
Who this helps: Patients with cancer who can benefit from tailored therapies based on their genetic profile.